SCHEMBL2469697

SCHEMBL2469697

CCOC(=O)/C=C/c1c(C)cc(/C(N)=N/O)cc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNKSR1 Q969H4 1/20 0.44
TTR P02766 1/20 0.43
DPP4 P27487 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CYP3A4 P08684 2/20 0.41
MAOB P27338 1/20 0.39
PTGS2 P35354 1/20 0.38
FDPS P14324 1/20 0.38
ESR1 P03372 2/20 0.38
HCAR2 Q8TDS4 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HSD17B1 P14061 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460666 1.00 CNKSR1 (0.44) CNKSR1TTRDPP4CA12CA1
SCHEMBL2469698 1.00 CNKSR1 (0.44) CNKSR1TTRDPP4CA12CA1
SCHEMBL2460667 1.00 CNKSR1 (0.44) CNKSR1TTRDPP4CA12CA1
SCHEMBL1741093 0.92 CNKSR1 (0.41) CNKSR1TTRDPP4CA12CA1
SCHEMBL2473600 0.92 CNKSR1 (0.41) CNKSR1TTRDPP4CA12CA1
SCHEMBL2473599 0.92 CNKSR1 (0.41) CNKSR1TTRDPP4CA12CA1
SCHEMBL1741091 0.92 CNKSR1 (0.41) CNKSR1TTRDPP4CA12CA1
SCHEMBL12129706 0.86 TTR (0.38) TTRCA12CA1CA2CA7
SCHEMBL12336812 0.83 LMNA (0.35) LMNAGFERKMT2AL3MBTL1MAPT
SCHEMBL13262958 0.83 ESR1 (0.51) TTRDPP4CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
EP-2370431-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE Almirall S.A. (ES) 2011-10-05 EP disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE S1PR1, S1PR2, S1PR3 CNKSR1 1654/4885TTR 4441/4885DPP4 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.